A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors - Trial NCT06258408
Access comprehensive clinical trial information for NCT06258408 through Pure Global AI's free database. This Phase 1 trial is sponsored by BrodenBio Co., Ltd. and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 78 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
BrodenBio Co., Ltd.
Timeline & Enrollment
Phase 1
Dec 29, 2022
Jul 01, 2025
Primary Outcome
Number of subjects with dose limiting toxicities (DLTs),Number of subjects with adverse events (AEs) and serious adverse events (SAEs)
Summary
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and
 preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as
 monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation
 phase and expansion phase.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06258408
Non-Device Trial